The M12-backed healthcare data management platform is speaking to new investors and is targeting between $50m and $60m at a $300m valuation.
The company has revealed it added approximately $6m to a series A round co-led by AbbVie Ventures last year, bringing its total size to about $59m.
Taiho, Memorial Sloan Kettering Cancer Center and Hartford HealthCare contributed to a round that boosted the cancer drug developer's total funding to more than $175m.
Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.
Bayer will pay up to $600 for the 59.2% stake in engineered-cell therapy developer BlueRock Therapeutics it does now own, following a $225m round in 2016.
The oncology-focused drug developer sourced $77m in the series D round, which was co-led by China Life Healthcare Fund.
The orphan disease drug developer's latest round was led by Novo while Asahi Kasei and Chiesi Ventures also participated, taking its overall funding to $46m.
Hillrom is paying $130m to snap up Johnson & Johnson-backed respiratory therapy system developer Breathe, which had raised at least $62m in funding.
Celgene and Astellas Venture Management each supplied a portion of the round to bring the Caltech-founded cancer drug developer's lifetime funding to $92m.
Robert Bosch Venture Capital has returned for a $13.5m round that came four years after the diagnostic technology developer's series B.